Century Therapeutics, Inc. · NASDAQ:IPSC
Century Therapeutics — 21st Annual Needham Virtual Healthcare Conference (April 2022)
17 slides from Century Therapeutics's conference presentation, Apr 13, 2022
Slide 1: 21st Annual Needham Virtual Healthcare Conference
1 April 13, 2022 21ST ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE
Slide 2: Forward-Looking Statements
2 2 FORWARD - LOOKING STATEMENTS This presentation contains forward - looking statements within the meaning of, and made pursuant to the safe harbour provisions of , The Private Securities Litigation Reform Act of 1995. All statements contained in this document, other than statements of historical f
Slide 3: Future Vision
3 3 Future Vision Century is developing transformative allogeneic cell therapies Establish franchises in B cell malignancies, GBM, solid tumor indications World - class cell engineering capabilities Develop best - in - class iPSC - derived iNK and iT cell platforms Financial strength maintained by p
Slide 4: Precision CRISPR MAD7 gene editing of iPSC cells unlocks transformational potential
4 4 Multiple gene edits (KO/KI) Product Candidate iPSC bank Sequential Precision Engineering Manufacturing PRECISION CRISPR MAD7 GENE EDITING OF I PSC CELLS UNLOCKS TRANSFORMATIONAL POTENTIAL Engineered iPSC Master Cell Bank Differentiation • Precise gene editing (MAD 7) enables engineering of candi
Slide 5: Allo-Evasion 1.0 designed to overcome three major pathways of host vs graft rejection
5 5 ALLO - EVASION TM 1.0 DESIGNED TO OVERCOME THREE MAJOR PATHWAYS OF HOST VS GRAFT REJECTION b 2M KO (HLA - I) HLA - E KI CIITA KO (HLA - II) CD8 + T Cell CD4 + T Cell NK cell Deletion of β 2M, a protein required to express HLA - I on the cell surface prevents recognition by CD8 T cells Knock out
Slide 6: Century's protein sciences enables all aspects of protein engineering
6 6 CENTURY'S PROTEIN SCIENCES ENABLES ALL ASPECTS OF PROTEIN ENGINEERING OF OUR PRODUCT CANDIDATES Binder domains Transmembrane domain Signaling domains CAR Engineering • Enable fit - for - purpose CAR assembly • Multiple CAR formats for single - and multi - specific CARs • CAR Binder Discovery • C
Slide 7: State-of-the-art manufacturing
7 7 STATE - OF - THE ART MANUFACTURING • cGMP manufacturing facility expected to be operational in 2022 • 53,000 ft 2 facility • Capable of production of NK and T cells, as well as other cell types DESIGNED TO POSITION CENTURY AS LEADER IN i PSC - BASED CELL THERAPY FOR CANCER Century’s multi - suit
Slide 8: Cell engineering enables rapid product iteration
8 8 CELL ENGINEERING ENABLES RAPID PRODUCT ITERATION iNK 1.0 Fit for purpose tailored functionality iNK 3.0 Century’s Platform allows for potentially transformative product evolution illustrative Proposed Feature CNTY - 101 iNK 1.0 CNTY - 103 iNK 2.0 iNK 3.0 Illustrative Cytokine support Soluble IL
Slide 9: Century's first generation gd CAR-iT cells multiple built-in pathways for tumor killing
9 9 CENTURY’S FIRST GENERATION gd CAR - i T CELLS MULTIPLE BUILT - IN PATHWAYS FOR TUMOR KILLING PATHWAYS FOR POTENTIAL TUMOR KILLING 1. CAR - mediated killing 2. ADCC (Antibody - dependent cellular cytotoxicity) 3. Innate - receptor mediated killing (NKG2D, others) 1 2 3
Slide 10: γδ CAR-iT cells kill lymphoma cells through multiple rounds of killing
10 10 γδ CAR - i T CELLS KILL LYMPHOMA CELLS THROUGH MULTIPLE ROUNDS OF KILLING WITHOUT REACHING EXHAUSTION Not for further distribution Serial Killing of CD19 + Lymphoma Cells by γδ CAR - iT cells 0 100 200 300 0 500000 1000000 1500000 Time Elapsed (hours) L i v e t u m o r c e l l s ( f l u o r e
Slide 11: Century's emerging franchises
11 11 CENTURY’S EMERGING FRANCHISES B cell malignancies Glioblastoma Solid tumors • CNTY - 101 : Lead product candidate, CD19 targeted CAR - iNK • CNTY - 102 : First gd iT candidate, multi - specific (CD19 + CD79b) CAR - iT • CNTY - 103 : Multi - specific (CD133+ EGFR) CAR iNK for recurrent GBM • Fo
Slide 12: ELiPSE-1 Phase 1 study design
12 12 ELIPSE - 1: PHASE 1 STUDY DESIGN* • Explore 1 to 2 cycles up to 6 doses with single LD conditioning • Effect of Allo - Evasion on iNK persistence after multiple doses • IND expected mid - 2022 to advance CNTY - 101 into Phase 1 clinical trial CNTY - 101: NEXT GENERATION CD19 TARGETED PRODUCT C
Slide 13: CNTY-103: First program in CNS malignancies
13 13 CNTY - 103: FIRST PROGRAM IN CNS MALIGNANCIES UNIQUELY POSITIONED TO ADDRESS CHALLENGES OF GBM HLA - I Knockout HLA - II Knockout Multi - specific EGFR/CD133 CAR Allo - Ev asi on edits HLA - E IL - 15/R a (membrane - bound) Challenge Century’s Solution Trafficking Local delivery with Ommaya re
Slide 14: Multiple CAR designs and signaling domains investigated for CD133 x EGFR CAR
14 MULTIPLE CAR DESIGNS AND SIGNALING DOMAINS WERE INVESTIGATED TO DEVELOP THE CD133 x EGFR CAR TMD CD28 CD3z HINGE CD133 & EGFR BINDING DOMAINS CNTY - 103 CAR CD133xEGFR 0 20 40 60 0.0 0.5 1.0 1.5 2.0 2.5 Time (hr) T u m o r c e l l f r e q u e n c y CD28+CD3Z - CAR 41BB+CD3Z - CAR DAP10+CD3Z - CAR
Slide 15: Pipeline
15 15 Product iPSC Platform Targets Indications Expected IND Submission Discovery Preclinical Clinical Collaborator CNTY - 101 iNK CD19 B - Cell Malignancies Mid 2022 CNTY - 103 iNK CD133 + EGFR Glioblastoma 2023 CNTY - 102 iT CD19 + CD79b B - Cell Malignancies 2024 CNTY - 104 iNK/ iT Multi - specif
Slide 16: Century Therapeutics' unique investment opportunity
16 16 CENTURY THERAPEUTICS’ UNIQUE INVESTMENT OPPORTUNITY • Well capitalized with cash runway into 2025 • Financial strength maintained by operational synergies • Comprehensive end - to - end allogeneic platform • iPSC derived iNK and iT cells, world - class gene editing, protein engineering and man
Slide 17: Century Therapeutics
CENTURY THERAPEUTICS
Century Therapeutics — 21st Annual Needham Virtual Healthcare Conference (April 2022) on 6ix